Certain doses of Eli Lilly's (LLY) GLP-1 weight loss drugs Zepbound and Mounjaro are facing a supply shortage, much like competitor Novo Nordisk's (NVO) own weight-loss treatment Wegovy. Eli Lilly is now considering releasing vials of their treatments for consumers capable of self-administering the drug. The #ReleaseTheVials campaign across social media is pressuring the pharmaceutical company to go this route for quicker, easier consumer access. On The Pen Live Host Dave Knapp talks about his experience using various treatment methods after a Type 2 Diabetes diagnosis and the major supply and demand imbalances occurring around the pharmaceutical trend. "Even though... you've seen them [Eli Lilly] announce major investments in the United States in manufacturing... they just can't keep up with 100,000 precipitations a week. You saw Eli Lilly and Zepbound specifically eclipse Wegovy..." Knapp tells Yahoo Finance. "You saw Zepbound eclipse Wegovy for the first time in new prescriptions just a week ago. And there's just no way they can keep up with that when you consider the complexity of the pens and the manufacturing of these very, very difficult — [Eli Lilly CEO] Dave Rick's own words — some of the most complex things to manufacture in the country." For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.

Read more --->